Ten-year prognostic impact of target versus non-target vessel failure after STEMI. Insight from the EXAMINATION-EXTEND trial.

Fallo del vaso diana Infarto de miocardio con elevación del segmento ST Intervención coronaria percutánea Percutaneous coronary intervention ST-segment myocardial infarction Target vessel failure

Journal

Revista espanola de cardiologia (English ed.)
ISSN: 1885-5857
Titre abrégé: Rev Esp Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101587954

Informations de publication

Date de publication:
26 Jul 2023
Historique:
received: 21 03 2023
accepted: 04 07 2023
pubmed: 29 7 2023
medline: 29 7 2023
entrez: 28 7 2023
Statut: aheadofprint

Résumé

After ST-segment myocardial infarction (STEMI), the impact of different adverse events on prognosis remains unknown. We aimed to assess very long-term predictors of patient-oriented composite endpoints (POCE) and investigate whether the occurrence of target vessel failure (TVF) vs a non-TVF event as the first event could potentially influence subsequent outcomes. The EXAMINATION.EXTEND trial randomized STEMI patients to receive either an everolimus-eluting stent or a bare-metal stent. The follow-up period was 10 years. Predictors of POCE (a composite of all-cause death, any myocardial infarction, or any revascularization) were evaluated in the overall study population. The patients were stratified based on the type of first event (TVF-first vs non-TVF-first) and were compared in terms of subsequent POCE. TVF was defined as a composite of cardiac death, TV myocardial infarction, or TV revascularization. Out of the 1498 enrolled patients, 529 (35.3%) experienced a POCE during the 10-year follow-up. Independent predictors of POCE were age, diabetes mellitus, previous myocardial infarction, peripheral arterial disease, and multivessel coronary disease. The first event was a TVF in 296 patients and was a non-TVF in 233 patients. No significant differences were observed between TVF-first and non-TVF-first patients in terms of subsequent POCE (21.7% vs 39.3%, time ratio 1.79; 95%CI, 0.87-3.67; P=.12) or its individual components. At the 10-year follow-up, approximately one-third of STEMI patients had experienced at least 1 POCE. Independent predictors of these events were age, diabetes, and more extensive atherosclerotic disease. The occurrence of a TVF or a non-TVF as the first event did not seem to influence subsequent outcomes. NCT04462315.

Identifiants

pubmed: 37506972
pii: S1885-5857(23)00202-5
doi: 10.1016/j.rec.2023.07.001
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04462315']

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Filippo Maria Verardi (FM)

Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain; Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.

Kamil Bujak (K)

Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain; 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.

Paolo Tolomeo (P)

Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.

Josep Gómez-Lara (J)

Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Víctor Jiménez-Díaz (V)

Departamento de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain; Investigación Cardiovascular, Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), Servizo Galego de Saúde-Universidade de Vigo (SERGAS-UVIGO), Vigo, Pontevedra, Spain.

Marcelo Jiménez (M)

Departamento de Cardiología, Hospital Universitari Sant Pau, Barcelona, Spain.

Pilar Jiménez-Quevedo (P)

Departamento de Cardiología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, Spain.

Roberto Diletti (R)

Thoraxcenter, Rotterdam, the Netherlands.

Pascual Bordes (P)

Departamento de Cardiología, Hospital General de Alicante, Alicante, Spain.

Gianluca Campo (G)

Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.

Antonio Silvestro (A)

Cardiology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.

Jaume Maristany (J)

Departamento de Cardiología, Hospital Son Dureta, Palma de Mallorca, Spain.

Xacobe Flores (X)

Departamento de Cardiología, Hospital Universitario de A Coruña, A Coruña, Spain.

Antonio de Miguel-Castro (A)

Departamento de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain.

Andrés Íñiguez (A)

Departamento de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain.

Alfonso Ielasi (A)

Cardiology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.

Maurizio Tespili (M)

Cardiology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.

Mattie Lenzen (M)

Thoraxcenter, Rotterdam, the Netherlands.

Nieves Gonzalo (N)

Departamento de Cardiología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, Spain.

Matteo Tebaldi (M)

Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.

Simone Biscaglia (S)

Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.

Pablo Vidal-Cales (P)

Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain.

Luis Ortega-Paz (L)

Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain; Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, United States.

Rafael Romaguera (R)

Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Joan Antoni Gómez-Hospital (JA)

Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Patrick W Serruys (PW)

Department of Cardiology, National University of Ireland, Galway, Ireland.

Manel Sabaté (M)

Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain.

Salvatore Brugaletta (S)

Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain. Electronic address: sabrugaletta@gmail.com.

Classifications MeSH